TScan enters ATM equity offering with Wedbush, up to 2% commission

TScan Therapeutics, Inc.

Entered Sales Agreement with Wedbush Securities for at-the-market issuance of common stock.
Commission of up to 2.0% of gross proceeds; Company sets sale parameters.
Shelf registration statement (333-268260) declared effective May 16, 2023; prospectus supplement filed.
No obligation to sell; either party may suspend or terminate offering on notice.
Sales may also be made to Wedbush as principal at agreed prices; customary indemnification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.